SCHEMBL3522683

SCHEMBL3522683

CN(C)c1ccc(C(CC(=O)O)NC(=O)c2ccc(Cl)cc2)cc1

nearest known ligand 0.72

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 17/20 0.72
ALDH1A1 P00352 1/20 0.57
POLB P06746 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
CYP26A1 O43174 1/20 0.57
KDM4E B2RXH2 1/20 0.54
GAA P10253 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5926658 0.86 UTS2R (0.59) UTS2R
SCHEMBL7822835 0.84 KDM4E (0.67) UTS2RCYP26A1KDM4EGAA
Oxalic Acid SCHEMBL5458498 0.83 UTS2R (0.93) UTS2R
SCHEMBL5926409 0.82 UTS2R (0.54) UTS2R
SCHEMBL27670347 0.82 KDM4E (0.54) UTS2RCYP26A1KDM4EGAA
SCHEMBL5927389 0.78 UTS2R (0.63) UTS2RCYP26A1KDM4EGAA
SCHEMBL15655244 0.76 CYP26A1 (0.58) CYP26A1
SCHEMBL4731512 0.73 UTS2R (1.00) UTS2R
SCHEMBL4731498 0.73 UTS2R (1.00) UTS2R
SCHEMBL14203062 0.73 UTS2R (1.00) UTS2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1737809-A4 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AMGEN INC (US) 2007-10-17 EP claimed
US-20070142384-A1 Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders AMGEN INC. (US) 2007-06-21 US claimed
EP-1737809-A2 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS Amgen, Inc (US) 2007-01-03 EP claimed
US-20060004012-A1 Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders AMGEN INC. 2006-01-05 US claimed
WO-2005086661-A2 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AMGEN INC. (US) 2005-09-22 WO claimed
US-7816367-B2 Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders AMGEN INC. (US) 2010-10-19 US disclosed
US-7649110-B2 Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders AMGEN INC. (US) 2010-01-19 US disclosed
EP-1737809-A4 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AMGEN INC (US) 2007-10-17 EP disclosed
US-20070142384-A1 Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders AMGEN INC. (US) 2007-06-21 US disclosed
CN-1946666-A Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders AMGEN INC (US) 2007-04-11 CN disclosed
EP-1737809-A2 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS Amgen, Inc (US) 2007-01-03 EP disclosed
US-20060004012-A1 Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders AMGEN INC. 2006-01-05 US disclosed
WO-2005086661-A2 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AMGEN INC. (US) 2005-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004012-A1 Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders PNLIP, IAPP, GPR119 UTS2R 2742/4885ALDH1A1 1567/4885POLB 3170/4885
US-20070142384-A1 Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders PNLIP, IAPP, GPR119 UTS2R 2742/4885ALDH1A1 1567/4885POLB 3170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.